Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RYBREVANT 2240 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RYBREVANT 2240 MG SOLUCION INYECTABLE

Approved

STANDARD

RYBREVANT 2240 MG SOLUCION INYECTABLE

Janssen-Cilag International N.V🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 14, 2025
Approval ID: 87a9bb14789dc8be
Company: Janssen-Cilag International N.V
Type: Standard

Approval Details

Approval Id: 87a9bb14789dc8be
Drug Cima Aemps Name: RYBREVANT 2240 MG SOLUCION INYECTABLE
Register Number: 1211594003
Holder Company Name: Janssen-Cilag International N.V
Marketing Company Name: Janssen Cilag S.A.
Holder Company Detail Path: /organization/01c9e6e3ee1a82cf/janssen-cilag-international-nv
Authorization Date: 2025-04-14
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 160 mg/ml
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Janssen-Cilag International N.V
Company Detail Path: /organization/01c9e6e3ee1a82cf/janssen-cilag-international-nv

Company Information

Pharmaceutical Company Name: Janssen-Cilag International NV
Country Name: Belgium

Active Ingredients

AMIVANTAMAB

2240 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 14, 2025

Approval ID

87a9bb14789dc8be

Type

Standard

Back to CIMA-AEMPS Approvals